Veraxa Biotech AG (VRXA)
VRXA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.20
+5.26% on the day
Market cap
$169.7M
Micro cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | VRXA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Switzerland |
| IPO year | Not reported by the screener |
| SEC CIK | 0002079109 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | V8 |
Financials
New registrant: no annual report filed under this company yet.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-04 |
| Latest annual report | 20-F | 2026-06-16 |
| Latest quarterly / interim | 6-K | 2026-09-04 |
Source: SEC EDGAR submissions feed, 53 recent filings. All filings on EDGAR.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| VRXAW | Veraxa Biotech AG Warrants | $0.0318 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| WHWK | Whitehawk Therapeutics Inc. | $3.02 | -10.65% | $172.2M |
| YARW | Yarrow Bioscience Inc. | $18.60 | -6.16% | $173.1M |
| PEPG | PepGen Inc. | $2.50 | +0.40% | $173.1M |
| NGEN | NervGen Pharma Corp. | $1.63 | -5.78% | $173.5M |
| ORMP | Oramed Pharmaceuticals Inc. | $4.17 | -2.34% | $173.5M |
| ADAG | Adagene Inc. | $2.46 | -10.22% | $162.5M |
| CNTN | Canton Strategic Holdings Inc. | $2.02 | -4.26% | $161.0M |
| DERM | Journey Medical Corporation | $5.68 | -3.89% | $160.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier